{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,13]],"date-time":"2026-09-13T09:05:29Z","timestamp":1789290329633,"version":"build-2803163510"},"reference-count":73,"publisher":"Springer Science and Business Media LLC","issue":"5","license":[{"start":{"date-parts":[[2026,8,18]],"date-time":"2026-08-18T00:00:00Z","timestamp":1787011200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0"},{"start":{"date-parts":[[2026,8,18]],"date-time":"2026-08-18T00:00:00Z","timestamp":1787011200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0"}],"funder":[{"DOI":"10.13039\/501100006692","name":"Universit\u00e0 degli Studi di Torino","doi-asserted-by":"crossref","id":[{"id":"10.13039\/501100006692","id-type":"DOI","asserted-by":"crossref"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["BioDrugs"],"published-print":{"date-parts":[[2026,9]]},"DOI":"10.1007\/s40259-026-00799-5","type":"journal-article","created":{"date-parts":[[2026,8,18]],"date-time":"2026-08-18T02:28:55Z","timestamp":1787020135000},"page":"763-776","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["Targeting CD38 Across Autoimmune and Plasma Cell\u2013Driven Immune-Mediated Diseases: Rationale, Clinical Evidence, and Emerging Therapeutic Landscape"],"prefix":"10.1007","volume":"40","author":[{"given":"Dario","family":"Roccatello","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Savino","family":"Sciascia","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Daniela","family":"Rossi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Roberta","family":"Fenoglio","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,8,18]]},"reference":[{"key":"799_CR1","doi-asserted-by":"publisher","DOI":"10.1016\/j.autrev.2026.104029","author":"C Guo","year":"2026","unstructured":"Guo C, Lei Z, Zhao L, Wei P. Precision immunotherapies for systemic lupus erythematosus: from pathogenic targets to translational horizons. Autoimmun Rev. 2026. https:\/\/doi.org\/10.1016\/j.autrev.2026.104029.","journal-title":"Autoimmun Rev"},{"key":"799_CR2","doi-asserted-by":"publisher","DOI":"10.1016\/j.kint.2026.01.032","author":"JT Kurzhagen","year":"2026","unstructured":"Kurzhagen JT, Laqua W, Schett G, Grieshaber-Bouyer R, Rabb H, Noel S, et al. Tiny warriors, big impact: targeted immunotherapy in kidney diseases. Kidney Int. 2026. https:\/\/doi.org\/10.1016\/j.kint.2026.01.032.","journal-title":"Kidney Int"},{"issue":"10","key":"799_CR3","doi-asserted-by":"publisher","first-page":"754","DOI":"10.1016\/j.autrev.2012.02.001","volume":"11","author":"SM Hayter","year":"2012","unstructured":"Hayter SM, Cook MC. Updated assessment of the prevalence, spectrum and case definition of autoimmune disease. Autoimmun Rev. 2012;11(10):754\u201365.","journal-title":"Autoimmun Rev"},{"issue":"25","key":"799_CR4","doi-asserted-by":"publisher","first-page":"2572","DOI":"10.1056\/NEJMoa032534","volume":"350","author":"JC Edwards","year":"2004","unstructured":"Edwards JC, Szczepanski L, Szechinski J, Filipowicz-Sosnowska A, Emery P, Close DR, et al. Efficacy of B-cell-targeted therapy with rituximab in patients with rheumatoid arthritis. N Engl J Med. 2004;350(25):2572\u201381.","journal-title":"N Engl J Med"},{"issue":"1 Suppl","key":"799_CR5","doi-asserted-by":"publisher","first-page":"S3","DOI":"10.37765\/ajmc.2026.89888","volume":"32","author":"A Dean","year":"2026","unstructured":"Dean A. Immune thrombocytopenia: contemporary pathophysiology, treatment gaps, and the role of novel mechanisms in patient-centered care. Am J Manag Care. 2026;32(1 Suppl):S3\u201311.","journal-title":"Am J Manag Care"},{"issue":"6","key":"799_CR6","doi-asserted-by":"publisher","first-page":"2194","DOI":"10.1172\/JCI78084","volume":"125","author":"J Suurmond","year":"2015","unstructured":"Suurmond J, Diamond B. Autoantibodies in systemic autoimmune diseases: specificity and pathogenicity. J Clin Invest. 2015;125(6):2194\u2013202.","journal-title":"J Clin Invest"},{"issue":"1","key":"799_CR7","doi-asserted-by":"publisher","DOI":"10.1002\/eji.202149675","volume":"53","author":"A Merino-Vico","year":"2023","unstructured":"Merino-Vico A, Frazzei G, van Hamburg JP, Tas SW. Targeting B cells and plasma cells in autoimmune diseases: from established treatments to novel therapeutic approaches. Eur J Immunol. 2023;53(1):e2149675.","journal-title":"Eur J Immunol"},{"issue":"1","key":"799_CR8","doi-asserted-by":"publisher","first-page":"103","DOI":"10.1146\/annurev-immunol-083122-044829","volume":"42","author":"I Abeles","year":"2024","unstructured":"Abeles I, Palma C, Meednu N, Payne AS, Looney RJ, Anolik JH. B cell-directed therapy in autoimmunity. Annu Rev Immunol. 2024;42(1):103\u201326.","journal-title":"Annu Rev Immunol"},{"issue":"4","key":"799_CR9","doi-asserted-by":"publisher","DOI":"10.1136\/rmdopen-2023-003604","volume":"9","author":"MT Holzer","year":"2023","unstructured":"Holzer MT, Ruffer N, Huber TB, K\u00f6tter I, Ostendorf L, Krusche M. Daratumumab for autoimmune diseases: a systematic review. RMD Open. 2023;9(4):e003604.","journal-title":"RMD Open"},{"key":"799_CR10","doi-asserted-by":"crossref","unstructured":"Verhoeven D, Grinwis L, Marsman C, Jansen MH, T2B Consortium, Van Leeuwen EM, Kuijpers TW. B-cell targeting with anti-CD38 daratumumab: implications for differentiation and memory responses. Life Sci Alliance. 2023;6(9):e202302214.","DOI":"10.26508\/lsa.202302214"},{"key":"799_CR11","doi-asserted-by":"crossref","unstructured":"Horenstein AL, Frerichs KA, Faini AC, van de Donk NWCJ, Malavasi F. Modulating CD38 enzymatic activity during antibody-based immunotherapy in multiple myeloma: a basic science perspective. Front. Immunol. 2026.","DOI":"10.3389\/fimmu.2026.1769281"},{"issue":"7","key":"799_CR12","doi-asserted-by":"publisher","DOI":"10.1016\/j.celrep.2024.114379","volume":"43","author":"W Pan","year":"2024","unstructured":"Pan W, Tsokos MG, Scherlinger M, Li W, Tsokos GC. The PP2A regulatory subunit PPP2R2A controls NAD+ biosynthesis to regulate T cell subset differentiation in systemic autoimmunity. Cell Rep. 2024;43(7):114379.","journal-title":"Cell Rep"},{"key":"799_CR13","doi-asserted-by":"crossref","unstructured":"Chen PM, Katsuyama E, Satyam A, Li H, Rubio J, Jung S, Andrzejewski S, Becherer JD, Tsokos MG, Abdi R, Tsokos GC. CD38 reduces mitochondrial fitness and cytotoxic T cell response against viral infection in lupus patients by suppressing mitophagy. Sci Adv. 2022;8(24):eabo4271.","DOI":"10.1126\/sciadv.abo4271"},{"issue":"1","key":"799_CR14","doi-asserted-by":"publisher","first-page":"112","DOI":"10.1016\/j.celrep.2019.12.014","volume":"30","author":"E Katsuyama","year":"2020","unstructured":"Katsuyama E, Suarez-Fueyo A, Bradley SJ, Mizui M, Marin AV, Mulki L, et al. The CD38\/NAD\/SIRTUIN1\/EZH2 axis mitigates cytotoxic CD8 T cell function and identifies patients with SLE prone to infections. Cell Rep. 2020;30(1):112-123.e4.","journal-title":"Cell Rep"},{"issue":"1","key":"799_CR15","doi-asserted-by":"publisher","first-page":"2","DOI":"10.1016\/j.tracli.2017.12.001","volume":"25","author":"V Deneys","year":"2018","unstructured":"Deneys V, Thiry C, Frelik A, Debry C, Martin B, Doyen C. Daratumumab: therapeutic asset, biological trap! Transfus Clin Biol. 2018;25(1):2\u20137.","journal-title":"Transfus Clin Biol"},{"key":"799_CR16","doi-asserted-by":"publisher","DOI":"10.1016\/j.biopha.2022.113395","author":"W Li","year":"2022","unstructured":"Li W, Liang L, Liao Q, Li Y, Zhou Y. CD38: an important regulator of T cell function. Biomed Pharmacother. 2022. https:\/\/doi.org\/10.1016\/j.biopha.2022.113395.","journal-title":"Biomed Pharmacother"},{"issue":"11","key":"799_CR17","doi-asserted-by":"publisher","DOI":"10.3390\/ijms21114129","volume":"21","author":"D Roccatello","year":"2020","unstructured":"Roccatello D, Fenoglio R, Sciascia S, Naretto C, Rossi D, Ferro M, et al. CD38 and anti-CD38 monoclonal antibodies in AL amyloidosis: targeting plasma cells and beyond. Int J Mol Sci. 2020;21(11):4129.","journal-title":"Int J Mol Sci"},{"key":"799_CR18","doi-asserted-by":"publisher","DOI":"10.3389\/ti.2025.14343","volume":"38","author":"KA Mayer","year":"2025","unstructured":"Mayer KA, Budde K, Diebold M, Halloran PF, B\u00f6hmig GA. Targeting CD38 in antibody-mediated rejection. Transpl Int. 2025;38:14343.","journal-title":"Transpl Int"},{"issue":"6","key":"799_CR19","doi-asserted-by":"publisher","first-page":"605","DOI":"10.1038\/s41590-020-0677-6","volume":"21","author":"GC Tsokos","year":"2020","unstructured":"Tsokos GC. Autoimmunity and organ damage in systemic lupus erythematosus. Nat Immunol. 2020;21(6):605\u201314. https:\/\/doi.org\/10.1038\/s41590-020-0677-6.","journal-title":"Nat Immunol"},{"issue":"8","key":"799_CR20","doi-asserted-by":"publisher","first-page":"1332","DOI":"10.1038\/s41590-024-01898-7","volume":"25","author":"GC Tsokos","year":"2024","unstructured":"Tsokos GC. The immunology of systemic lupus erythematosus. Nat Immunol. 2024;25(8):1332\u201343.","journal-title":"Nat Immunol"},{"issue":"1","key":"799_CR21","doi-asserted-by":"publisher","DOI":"10.1038\/s41467-026-69112-w","volume":"17","author":"L Ostendorf","year":"2026","unstructured":"Ostendorf L, Zernicke J, Klotsche J, Kempkens R, Beenken AE, Biesen R, et al. Daratumumab in systemic lupus erythematosus: a single-arm phase 2 trial. Nat Commun. 2026;17(1):1312.","journal-title":"Nat Commun"},{"issue":"12","key":"799_CR22","doi-asserted-by":"publisher","first-page":"1149","DOI":"10.1056\/NEJMoa2023325","volume":"383","author":"L Ostendorf","year":"2020","unstructured":"Ostendorf L, Burns M, Durek P, Heinz GA, Heinrich F, Garantziotis P, et al. Targeting CD38 with daratumumab in refractory systemic lupus erythematosus. N Engl J Med. 2020;383(12):1149\u201355.","journal-title":"N Engl J Med"},{"issue":"8","key":"799_CR23","doi-asserted-by":"publisher","first-page":"2041","DOI":"10.1038\/s41591-023-02479-1","volume":"29","author":"D Roccatello","year":"2023","unstructured":"Roccatello D, Fenoglio R, Caniggia I, Kamgaing J, Naretto C, Cecchi I, et al. Daratumumab monotherapy for refractory lupus nephritis. Nat Med. 2023;29(8):2041\u20137.","journal-title":"Nat Med"},{"key":"799_CR24","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2022.805697","volume":"13","author":"B Basu","year":"2022","unstructured":"Basu B, Angeletti A, Islam B, Ghiggeri GM. New and old anti-CD20 monoclonal antibodies for nephrotic syndrome. Where we are? Front Immunol. 2022;13:805697.","journal-title":"Front Immunol"},{"key":"799_CR25","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2025.1624850","volume":"16","author":"C Dong","year":"2025","unstructured":"Dong C, Wu M, Liu H, Yang K, Ma S, Guo Y, et al. Breaking the cycle: immune complexes, complement activation, and novel immunotherapies in lupus nephritis. Front Immunol. 2025;16:1624850.","journal-title":"Front Immunol"},{"issue":"8","key":"799_CR26","doi-asserted-by":"publisher","DOI":"10.1111\/1756-185x.70395","volume":"28","author":"X Li","year":"2025","unstructured":"Li X, Liu X, Yin H, Lu L. Case report: daratumumab for a patient with refractory systemic lupus erythematosus and antiphospholipid syndrome presenting as thrombocytopenia. Int J Rheum Dis. 2025;28(8):e70395. https:\/\/doi.org\/10.1111\/1756-185x.70395.","journal-title":"Int J Rheum Dis"},{"key":"799_CR27","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2025.1525892","volume":"16","author":"DS Chiarenza","year":"2025","unstructured":"Chiarenza DS, Mancini R, Bigatti C, Caridi G, Consolaro A, Natoli V, et al. Case report: single infusion of combined anti-CD20 and anti-CD38 monoclonal antibodies in pediatric refractory lupus nephritis. Front Immunol. 2025;16:1525892.","journal-title":"Front Immunol"},{"key":"799_CR28","doi-asserted-by":"publisher","first-page":"39","DOI":"10.2147\/TCRM.S252592","volume":"17","author":"A Bag-Ozbek","year":"2021","unstructured":"Bag-Ozbek A, Hui-Yuen JS. Emerging B-cell therapies in systemic lupus erythematosus. Ther Clin Risk Manag. 2021;17:39\u201354. https:\/\/doi.org\/10.2147\/TCRM.S252592.","journal-title":"Ther Clin Risk Manag"},{"key":"799_CR29","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2021.645478","volume":"12","author":"M Humbel","year":"2021","unstructured":"Humbel M, Bellanger F, Fluder N, Horisberger A, Suffiotti M, Fenwick C, et al. Restoration of NK cell cytotoxic function with elotuzumab and daratumumab promotes elimination of circulating plasma cells in patients with SLE. Front Immunol. 2021;12:645478.","journal-title":"Front Immunol"},{"issue":"11","key":"799_CR30","doi-asserted-by":"publisher","first-page":"1497","DOI":"10.1136\/ard-2023-224152","volume":"82","author":"T Alexander","year":"2023","unstructured":"Alexander T, Ostendorf L, Biesen R, Schneider U, Burmester GR, Hiepe F. Sustained responses after anti-CD38 treatment with daratumumab in two patients with refractory systemic lupus erythematosus. Ann Rheum Dis. 2023;82(11):1497\u20139.","journal-title":"Ann Rheum Dis"},{"key":"799_CR31","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2021.667515","volume":"12","author":"DE Pleguezuelo","year":"2021","unstructured":"Pleguezuelo DE, D\u00edaz-Sim\u00f3n R, Cabrera-Marante O, Lalueza A, Paz-Artal E, Lumbreras C, et al. Case report: resetting the humoral immune response by targeting plasma cells with daratumumab in anti-phospholipid syndrome. Front Immunol. 2021;12:667515.","journal-title":"Front Immunol"},{"issue":"3","key":"799_CR32","doi-asserted-by":"publisher","first-page":"251","DOI":"10.1002\/ajh.21948","volume":"86","author":"SK Kumar","year":"2011","unstructured":"Kumar SK, Dispenzieri A, Lacy MQ, Hayman SR, Buadi FK, Zeldenrust SR, et al. Changes in serum-free light chain rather than intact monoclonal immunoglobulin levels predicts outcome following therapy in primary amyloidosis. Am J Hematol. 2011;86(3):251\u20135.","journal-title":"Am J Hematol"},{"issue":"2","key":"799_CR33","doi-asserted-by":"publisher","first-page":"110","DOI":"10.3109\/13506120309041732","volume":"10","author":"M Matsuda","year":"2003","unstructured":"Matsuda M, Gono T, Shimojima Y, Hoshii Y, Ikeda S. Phenotypic analysis of plasma cells in bone marrow using flow cytometry in AL amyloidosis. Amyloid. 2003;10(2):110\u20136.","journal-title":"Amyloid"},{"key":"799_CR34","doi-asserted-by":"publisher","first-page":"2722","DOI":"10.3389\/fimmu.2018.02722","volume":"9","author":"AL Morandi","year":"2018","unstructured":"Morandi AL, Horenstein F, Costa N, Giuliani V, Pistoia F. Malavasi CD38: a target for immunotherapeutic approaches in multiple myeloma. Front Immunol. 2018;9:2722.","journal-title":"Front Immunol"},{"key":"799_CR35","doi-asserted-by":"publisher","unstructured":"Sanchorawala, S.D. Sarosiek, J.M. Sloan, D. Brauneis, M.E. Migre, M. Mistark, et al. Safety, tolerability and response rates of Daratumumab in patients with relapsed light chain (AL) amyloidosis: results of a phase II study. Blood. 2005;132 (Supplement 1). https:\/\/doi.org\/10.1182\/blood-2018-99-112991.","DOI":"10.1182\/blood-2018-99-112991"},{"issue":"9","key":"799_CR36","doi-asserted-by":"publisher","DOI":"10.1016\/j.autrev.2020.102622","volume":"19","author":"D Roccatello","year":"2020","unstructured":"Roccatello D, Fenoglio R, Baldovino S, Naretto C, Ferro M, Barreca A, et al. Towards a novel target therapy for renal diseases related to plasma cell dyscrasias: the example of AL amyloidosis. Autoimmun Rev. 2020;19(9):102622.","journal-title":"Autoimmun Rev"},{"issue":"10","key":"799_CR37","doi-asserted-by":"publisher","DOI":"10.3390\/jcm9103232","volume":"9","author":"D Roccatello","year":"2020","unstructured":"Roccatello D, Fenoglio R, Naretto C, Baldovino S, Sciascia S, Ferro M, et al. Daratumumab monotherapy in severe patients with AL amyloidosis and biopsy-proven renal involvement: a real life experience. J Clin Med. 2020;9(10):3232.","journal-title":"J Clin Med"},{"key":"799_CR38","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2021.649441","volume":"12","author":"A Zaninoni","year":"2021","unstructured":"Zaninoni A, Giannotta JA, Gall\u00ec A, Artuso R, Bianchi P, Malcovati L, et al. The immunomodulatory effect and clinical efficacy of Daratumumab in a patient with cold agglutinin disease. Front Immunol. 2021;12:649441.","journal-title":"Front Immunol"},{"key":"799_CR39","doi-asserted-by":"publisher","first-page":"4819","DOI":"10.1182\/blood.V128.22.4819.4819","volume":"128","author":"VP Tolbert","year":"2016","unstructured":"Tolbert VP, Goldsby R, Huang J, Shimano K, Melton A, Willert J, et al. Daratumumab is effective in the treatment of refractory post-transplant autoimmune hemolytic anemia: a pediatric case report. Blood. 2016;128:4819. https:\/\/doi.org\/10.1182\/blood.V128.22.4819.4819.","journal-title":"Blood"},{"key":"799_CR40","doi-asserted-by":"publisher","first-page":"2550","DOI":"10.1182\/bloodadvances.2018020883","volume":"2","author":"C Schuetz","year":"2018","unstructured":"Schuetz C, Hoenig M, Moshous D, Weinstock C, Castelle M, Bendavid M, et al. Daratumumab in life-threatening autoimmune hemolytic anemia following hematopoietic stem cell transplantation. Blood Adv. 2018;2:2550\u20133.","journal-title":"Blood Adv"},{"key":"799_CR41","doi-asserted-by":"publisher","first-page":"3801","DOI":"10.1111\/trf.15539","volume":"59","author":"L Cooling","year":"2019","unstructured":"Cooling L, Higan S. Daratumumab in combination with standard treatment for autoimmune hemolytic anemia in a pediatric patient. Transfusion. 2019;59:3801\u20132.","journal-title":"Transfusion"},{"key":"799_CR42","doi-asserted-by":"publisher","DOI":"10.1002\/pbc.28591","volume":"67","author":"J Koo","year":"2020","unstructured":"Koo J, Giller RH, Quinones R, McKinney CM, Verneris MR, Knight-Perry J. Autoimmune cytopenias following allogeneic hematopoietic stem cell transplant in pediatric patients: response to therapy and late effects. Pediatr Blood Cancer. 2020;67:e28591. https:\/\/doi.org\/10.1002\/pbc.28591.","journal-title":"Pediatr Blood Cancer"},{"key":"799_CR43","doi-asserted-by":"publisher","DOI":"10.1007\/s00277-020-04063-w","author":"A Jain","year":"2020","unstructured":"Jain A, Gupta DK. Daratumumab for refractory warm autoimmune haemolytic anemia. Ann Hematol. 2020. https:\/\/doi.org\/10.1007\/s00277-020-04063-w.","journal-title":"Ann Hematol"},{"key":"799_CR44","doi-asserted-by":"publisher","DOI":"10.1002\/ajh.25932","author":"O Tomkins","year":"2020","unstructured":"Tomkins O, Berentsen S, Arulogun S, Sekhar M, D\u2019Sa S. Daratumumab for disabling cold agglutinin disease refractory to B-cell directed therapy. Am J Hematol. 2020. https:\/\/doi.org\/10.1002\/ajh.25932.","journal-title":"Am J Hematol"},{"key":"799_CR45","doi-asserted-by":"publisher","DOI":"10.1002\/pbc.28010","volume":"67","author":"E Even-Or","year":"2020","unstructured":"Even-Or E, Naser Eddin A, Shadur B, Dinur Schejter Y, Najajreh M, Zelig O, et al. Successful treatment with daratumumab for post-HSCT refractory hemolytic anemia. Pediatr Blood Cancer. 2020;67:e28010. https:\/\/doi.org\/10.1002\/pbc.28010.","journal-title":"Pediatr Blood Cancer"},{"key":"799_CR46","doi-asserted-by":"publisher","first-page":"e48","DOI":"10.1111\/bjh.16171","volume":"187","author":"R Blennerhassett","year":"2019","unstructured":"Blennerhassett R, Sudini L, Gottlieb D, Bhattacharyya A. Post-allogeneic transplant Evans syndrome successfully treated with daratumumab. Br J Hematol. 2019;187:e48-51. https:\/\/doi.org\/10.1111\/bjh.16171.","journal-title":"Br J Hematol."},{"key":"799_CR47","doi-asserted-by":"publisher","first-page":"235","DOI":"10.1111\/j.1365-2141.2009.07615.x","volume":"145","author":"WM Schoonen","year":"2009","unstructured":"Schoonen WM, Kucera G, Coalson J, et al. Epidemiology of immune thrombocytopenic purpura in the General Practice Research Database. Br J Haematol. 2009;145:235\u2013324.","journal-title":"Br J Haematol"},{"issue":"3","key":"799_CR48","doi-asserted-by":"publisher","first-page":"909","DOI":"10.1182\/blood.V94.3.909.415k02_909_913","volume":"94","author":"H Frederiksen","year":"1999","unstructured":"Frederiksen H, Schmidt K. The incidence of idiopathic thrombocytopenic purpura in adults increases with age. Blood. 1999;94(3):909\u201313.","journal-title":"Blood"},{"key":"799_CR49","doi-asserted-by":"publisher","first-page":"945","DOI":"10.1056\/NEJMcp1810479","volume":"381","author":"N Cooper","year":"2019","unstructured":"Cooper N, Ghanima W. Immune thrombocytopenia. N Engl J Med. 2019;381:945\u201355.","journal-title":"N Engl J Med"},{"key":"799_CR50","doi-asserted-by":"publisher","DOI":"10.1038\/s41591-026-04366-x","author":"H Li","year":"2026","unstructured":"Li H, Xu Y, Chen Y, Ji L, Xu Y, Zheng W, et al. Low-dose oral nicotinamide mononucleotide for immune thrombocytopenia: a phase 1\/2 trial. Nat Med. 2026. https:\/\/doi.org\/10.1038\/s41591-026-04366-x.","journal-title":"Nat Med"},{"key":"799_CR51","doi-asserted-by":"publisher","first-page":"3829","DOI":"10.1182\/bloodadvances.2019000966","volume":"3","author":"C Neunert","year":"2019","unstructured":"Neunert C, Terrell DR, Arnold DM, et al. American Society of Hematology 2019 guidelines for immune thrombocytopenia. Blood Adv. 2019;3:3829\u201366.","journal-title":"Blood Adv"},{"issue":"23","key":"799_CR52","doi-asserted-by":"publisher","first-page":"2178","DOI":"10.1056\/NEJMoa2400409","volume":"390","author":"Y Chen","year":"2024","unstructured":"Chen Y, Xu Y, Li H, Sun T, Cao X, Wang Y, et al. A novel anti-CD38 monoclonal antibody for treating immune thrombocytopenia. N Engl J Med. 2024;390(23):2178\u201390.","journal-title":"N Engl J Med"},{"key":"799_CR53","doi-asserted-by":"publisher","DOI":"10.1136\/bmj-2025-084314","volume":"391","author":"Y Chen","year":"2025","unstructured":"Chen Y, Xu Y, Dai J, Sun T, Li H, Hua Z, et al. Anti-CD38 monoclonal antibody CM313 for primary immune thrombocytopenia: multicentre, randomised, placebo controlled, phase 2 trial. BMJ. 2025;391:e084314. https:\/\/doi.org\/10.1136\/bmj-2025-084314.","journal-title":"BMJ"},{"issue":"1","key":"799_CR54","doi-asserted-by":"publisher","first-page":"143","DOI":"10.1182\/bloodadvances.2025017279","volume":"10","author":"G Tsykunova","year":"2026","unstructured":"Tsykunova G, Holme PA, Tran HTT, Frederiksen H, Tj\u00f8nnfjord E, Munthe LA, et al. Safety and efficacy of daratumumab in immune thrombocytopenia. Blood Adv. 2026;10(1):143\u201354.","journal-title":"Blood Adv"},{"key":"799_CR55","doi-asserted-by":"publisher","DOI":"10.1016\/j.eclinm.2026.103849","volume":"94","author":"Y Chen","year":"2026","unstructured":"Chen Y, Hua Z, Xu Y, Chen J, Wen Q, Sun T, et al. Daratumumab in patients with immune thrombocytopenia: a single-center, open-label, phase 2 trial. EClinicalMedicine. 2026;94:103849.","journal-title":"EClinicalMedicine"},{"issue":"20","key":"799_CR56","doi-asserted-by":"publisher","first-page":"2069","DOI":"10.1056\/NEJMc2501527","volume":"392","author":"T Sun","year":"2025","unstructured":"Sun T, Chen Y, Zhang L. Daratumumab in relapsed or refractory pediatric immune thrombocytopenia. N Engl J Med. 2025;392(20):2069\u201371. https:\/\/doi.org\/10.1056\/NEJMc2501527.","journal-title":"N Engl J Med"},{"key":"799_CR57","doi-asserted-by":"publisher","first-page":"503","DOI":"10.1111\/bjh.15803","volume":"185","author":"DJ Kuter","year":"2019","unstructured":"Kuter DJ, Newland A, Chong BH, et al. Romiplostim in adult patients with newly diagnosed or persistent immune thrombocytopenia (ITP) for up to 1 year and in those with chronic ITP for more than 1 year: a subgroup analysis of integrated data from completed romiplostim studies. Br J Haematol. 2019;185:503\u201313.","journal-title":"Br J Haematol"},{"key":"799_CR58","doi-asserted-by":"publisher","first-page":"5468","DOI":"10.1182\/bloodadvances.2021005610","volume":"5","author":"B Fattizzo","year":"2021","unstructured":"Fattizzo B, Michel M, Giannotta JA, Hansen DL, Arguello M, Sutto E, et al. Evans syndrome in adults: an observational multicenter study. Blood Adv. 2021;5:5468\u201378.","journal-title":"Blood Adv"},{"key":"799_CR59","doi-asserted-by":"publisher","first-page":"e617","DOI":"10.1016\/S2352-3026(24)00144-3","volume":"11","author":"B Fattizzo","year":"2024","unstructured":"Fattizzo B, Marchetti M, Michel M, Cantoni S, Frederiksen H, Giordano G, et al. Diagnosis and management of Evans syndrome in adults: first consensus recommendations. Lancet Haematol. 2024;11:e617\u201328.","journal-title":"Lancet Haematol."},{"key":"799_CR60","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2019.02458","volume":"10","author":"I Sanz","year":"2019","unstructured":"Sanz I, Wei C, Jenks SA, Cashman KS, Tipton C, Woodruff MC, et al. Challenges and opportunities for consistent classification of human B cell and plasma cell populations. Front Immunol. 2019;10:3389\/fimmu.2019.02458.","journal-title":"Front Immunol"},{"key":"799_CR61","doi-asserted-by":"crossref","unstructured":"Hillmann SM. Daratumumab in severe Evans syndrome: a case report. Front. Hematol. 2026.","DOI":"10.3389\/frhem.2025.1719208"},{"issue":"5","key":"799_CR62","doi-asserted-by":"publisher","first-page":"1668","DOI":"10.1038\/s41591-025-03653-3","volume":"31","author":"M Diebold","year":"2025","unstructured":"Diebold M, Gauthier PT, Mayer KA, Mackova M, Hinze C, Chang J, et al. Effect of felzartamab on the molecular phenotype of antibody-mediated rejection in kidney transplant biopsies. Nat Med. 2025;31(5):1668\u201376.","journal-title":"Nat Med"},{"issue":"5","key":"799_CR63","doi-asserted-by":"publisher","first-page":"730","DOI":"10.1016\/j.kint.2025.06.023","volume":"108","author":"O Thaunat","year":"2025","unstructured":"Thaunat O, Colvin RB. Felzartamab: a magic bullet to treat microvascular rejection? Kidney Int. 2025;108(5):730\u20134.","journal-title":"Kidney Int"},{"key":"799_CR64","doi-asserted-by":"publisher","DOI":"10.1111\/sji.12664","volume":"87","author":"M Dom\u00ednguez-Pantoja","year":"2018","unstructured":"Dom\u00ednguez-Pantoja M, L\u00f3pez-Herrera G, Romero-Ram\u00edrez H, Santos-Argumedo L, Ch\u00e1vez-Rueda AK, Hern\u00e1ndez-Cueto A, et al. CD38 protein deficiency induces autoimmune characteristics and its activation enhances IL-10 production by regulatory B cells. Scand J Immunol. 2018;87:e12664.","journal-title":"Scand J Immunol"},{"key":"799_CR65","doi-asserted-by":"publisher","first-page":"2849","DOI":"10.1002\/art.38742","volume":"66","author":"N Gao","year":"2014","unstructured":"Gao N, Dresel J, Eckstein V, Gellert R, St\u00f6rch H, Venigalla RKC, et al. Impaired suppressive capacity of activation-induced regulatory b cells in systemic lupus erythematosus. Arthritis Rheumatol. 2014;66:2849\u201361.","journal-title":"Arthritis Rheumatol"},{"key":"799_CR66","first-page":"241","volume-title":"Current topics in microbiology and immunology","author":"RA Manz","year":"2006","unstructured":"Manz RA, Moser K, Burmester GR, Radbruch A, Hiepe F. Immunological memory stabilizing autoreactivity. In: Radbruch A, Lipsky PE, editors. Current topics in microbiology and immunology. Berlin\/Heidelberg: Springer; 2006. p. 241\u201357."},{"issue":"2","key":"799_CR67","doi-asserted-by":"publisher","DOI":"10.1097\/TXD.0000000000001908","volume":"12","author":"P Cravedi","year":"2026","unstructured":"Cravedi P, Maggiore U, Mortari G, Alberici F, La Manna G, Goes N, et al. Combined anti-CD20\/anti-CD38 therapy in posttransplant focal segmental glomerulosclerosis recurrence: a retrospective, international, multicenter study. Transplant Direct. 2026;12(2):e1908.","journal-title":"Transplant Direct"},{"issue":"11","key":"799_CR68","doi-asserted-by":"publisher","first-page":"2622","DOI":"10.1182\/bloodadvances.2024012585","volume":"8","author":"M Jalink","year":"2024","unstructured":"Jalink M, Jacobs CF, Khwaja J, Evers D, Bruggeman C, Fattizzo B, et al. Daratumumab monotherapy in refractory warm autoimmune hemolytic anemia and cold agglutinin disease. Blood Adv. 2024;8(11):2622\u201334.","journal-title":"Blood Adv"},{"issue":"3","key":"799_CR69","doi-asserted-by":"publisher","first-page":"410","DOI":"10.1080\/10428194.2023.2287963","volume":"65","author":"KN Shen","year":"2024","unstructured":"Shen KN, Zhao DQ, Mao YY, Cai HC, Li J, Cao XX. Daratumumab-based regimen for cold agglutinin disease refractory to therapy directing B-cell clone. Leuk Lymphoma. 2024;65(3):410\u20132.","journal-title":"Leuk Lymphoma"},{"issue":"5","key":"799_CR70","doi-asserted-by":"publisher","first-page":"355","DOI":"10.1159\/000535927","volume":"51","author":"F Frioni","year":"2024","unstructured":"Frioni F, Metafuni E, Limongiello MA, Piccirillo N, Massini G, Pellegrino C, et al. Posttransplant autoimmune hemolytic anemia with anti-D specificity successfully treated with daratumumab: a case report. Transfus Med Hemother. 2024;51(5):355\u20138.","journal-title":"Transfus Med Hemother"},{"issue":"39","key":"799_CR71","doi-asserted-by":"publisher","DOI":"10.1097\/MD.0000000000044874","volume":"104","author":"ZY Bian","year":"2025","unstructured":"Bian ZY, Xu L. A case report on the treatment of autoimmune hemolytic anemia after CBT by daratumumab in a mucopolysaccharidosis type III patient. Medicine (Baltimore). 2025;104(39):e44874.","journal-title":"Medicine (Baltimore)"},{"issue":"12","key":"799_CR72","doi-asserted-by":"publisher","DOI":"10.3390\/cells8121522","volume":"8","author":"TG Martin","year":"2019","unstructured":"Martin TG, Corzo K, Chiron M, van der Velde H, Abbadessa G, Campana F, et al. Therapeutic opportunities with pharmacological inhibition of CD38 with isatuximab. Cells. 2019;8(12):1522.","journal-title":"Cells"},{"issue":"1","key":"799_CR73","doi-asserted-by":"publisher","DOI":"10.1080\/19420862.2022.2095949","volume":"14","author":"HS Ugamraj","year":"2022","unstructured":"Ugamraj HS, Dang K, Ouisse LH, Buelow B, Chini EN, Castello G, et al. TNB-738, a biparatopic antibody, boosts intracellular NAD+ by inhibiting CD38 ecto-enzyme activity. MAbs. 2022;14(1):2095949.","journal-title":"MAbs"}],"container-title":["BioDrugs"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s40259-026-00799-5.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s40259-026-00799-5","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s40259-026-00799-5.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,9,13]],"date-time":"2026-09-13T09:02:43Z","timestamp":1789290163000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s40259-026-00799-5"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,8,18]]},"references-count":73,"journal-issue":{"issue":"5","published-print":{"date-parts":[[2026,9]]}},"alternative-id":["799"],"URL":"https:\/\/doi.org\/10.1007\/s40259-026-00799-5","relation":{},"ISSN":["1173-8804","1179-190X"],"issn-type":[{"value":"1173-8804","type":"print"},{"value":"1179-190X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,8,18]]},"assertion":[{"value":"2 July 2026","order":1,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"18 August 2026","order":2,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"The authors declare they have no conflicts of interest relevant to the contents of this article.","order":1,"name":"Ethics","label":"Conflict of Interest","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Not applicable.","order":2,"name":"Ethics","label":"Ethics Approval (appropriate approvals or waivers)","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Not applicable.","order":3,"name":"Ethics","label":"Consent to Participate","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Not applicable.","order":4,"name":"Ethics","label":"Consent for Publication","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Not applicable.","order":5,"name":"Ethics","label":"Availability of Data and Materials (Data Transparency)","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Not applicable.","order":6,"name":"Ethics","label":"Code Availability (Software Application or Custom Code)","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"DR conceived the manuscript. DR, SS, DRo, and RF contributed to the literature review, interpretation of the evidence, and drafting of the manuscript. SS and RF critically revised the manuscript for intellectual content. All authors reviewed and approved the final version.","order":7,"name":"Ethics","label":"Author Contributions","group":{"name":"EthicsHeading","label":"Declarations"}}]}}